SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Chromatics Color Sciences International. Inc; CCSI
CCSI 23.39+0.5%Dec 18 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Clayleas who wrote (1358)3/17/1998 9:20:00 AM
From: Spunky Beaver  Read Replies (1) of 5736
 
Yes it does. It is very likely that the AMA will create a new CPT code for non-invasive procedures once the device gains popularity and the number of non-evasive tests performed reaches a significant percentage of the total of hyperbilirubinemia test; say about 5%. At some time before or after that threshold is reached, the AMA will perform a detailed cost analysis of the procedure and readjust it's reimbursement rate accordingly.
In today's health care market, it is much more probable that the reimbursement rate for a replacement procedure will be adjusted downward instead of upward. However, the nature of the device lends itself to increased testing which would probably increase the total reimbursement dollars paid out for hyperbilirubinemia testing in the face of reduced reimbursement rates.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News